Conversely, miR-1246, enriched in AML cell-derived EVs, through its targeted repression of leucine rich repeats and immunoglobulin-like domains 1 (LRIG1), activates the signal transducer and activator of transcription 3 (STAT3) pathway, thereby increasing the viability and differentiation of LSCs (68). Here, LRIG1 is linked to acute myeloid leukemia.